ReVision Implant announced that it closed an oversubscribed €4 million capital round as the company advances its neurotechnology platform designed to restore vision in blind individuals. The funding will support scaling operations and moving the company’s preclinical research into clinical testing.
The company, which develops ultra flexible brain implants that bypass damaged eyes and transmit visual information directly to the visual cortex, has recently achieved several milestones. These include receiving FDA Breakthrough Device Designation, opening a new lab at the Leuven Bio-Incubator, securing a U.S. patent, and being named Deloitte’s Most Disruptive Innovator of 2025 at the Fast50 Rising Star awards.
ReVision Implant has also been highlighted by the European Innovation Council for its work in developing brain implant technology that could potentially restore functional vision for millions of blind individuals.
KEY QUOTES:
“The ReVision Implant team and I are happy to announce that we’ve closed an oversubscribed 4 M€ capital round! This is a key step for us , it will enable to upscale to bring the results of the preclinical research that we did over the last years to clinical testing. A big thanks to all our new and existing investors for their faith and support!”
“With great pleasure, I’m announcing that as of today we have been awarded FDA Breakthrough Device Designation! Special thanks to our whole ReVision Implant team and partners such as Peter Janssen and Gijs Klarenbeek that have made this possible.”
“The FDA Breakthrough Devices Program recognizes exceptional medical devices with the potential to significantly improve treatment of serious or life-altering conditions, providing prioritized FDA engagement to expedite their market access in the USA.”
Frederik Ceyssens, Co-Founder & CEO, ReVision Implant
